{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:49:25Z","timestamp":1794242965447,"version":"4.9.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006432","name":"Terumo BCT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006432","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ophtha.2021.05.008","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T11:28:33Z","timestamp":1620991713000},"page":"1748-1755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Ocular Safety Profile of BRAF and MEK Inhibitors"],"prefix":"10.1016","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1649-3175","authenticated-orcid":false,"given":"Camille","family":"Mettler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6846-6120","authenticated-orcid":false,"given":"Dominique","family":"Monnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Kramkimel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Tr\u00e9luyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Mouthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Br\u00e9zin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6237-4951","authenticated-orcid":false,"given":"Nicolas","family":"Dupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Blanche","family":"Valnet-Rabier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9626-3571","authenticated-orcid":false,"given":"Laurent","family":"Chouchana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Terrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2021.05.008_bib1","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2021.05.008_bib2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2021.05.008_bib3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2021.05.008_bib4","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2021.05.008_bib5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrclinonc.2014.83","article-title":"The clinical development of MEK inhibitors","volume":"11","author":"Zhao","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ophtha.2021.05.008_bib6","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ophtha.2021.05.008_bib7","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nrc.2017.79","article-title":"New perspectives for targeting RAF kinase in human cancer","volume":"17","author":"Karoulia","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ophtha.2021.05.008_bib8","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","article-title":"Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET Study","volume":"4","author":"Diamond","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ophtha.2021.05.008_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000491","article-title":"Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management","volume":"4","author":"Heinzerling","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.ophtha.2021.05.008_bib10","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ajo.2014.07.003","article-title":"Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib","volume":"158","author":"Choe","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.05.008_bib11","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/eye.2015.82","article-title":"MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity","volume":"29","author":"Duncan","year":"2015","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2021.05.008_bib12","first-page":"409","article-title":"VigiBase, the WHO Global ICSR Database System: Basic Facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.ophtha.2021.05.008_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40264-013-0131-x","article-title":"vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues","volume":"37","author":"Bergvall","year":"2014","journal-title":"Drug Saf"},{"issue":"259\u2013265","key":"10.1016\/j.ophtha.2021.05.008_bib14","first-page":"S1","article-title":"The Standardization of Uveitis Nomenclature (SUN) Project. Development of a clinical evidence base utilizing informatics tools and techniques","volume":"52","author":"Trusko","year":"2013","journal-title":"Methods Inf Med"},{"key":"10.1016\/j.ophtha.2021.05.008_bib15","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database: Commentary","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ophtha.2021.05.008_bib16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ophtha.2021.05.008_bib17","first-page":"465","article-title":"Reporting adverse drug reactions","volume":"304","author":"Delamothe","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.ophtha.2021.05.008_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12348-017-0135-2","article-title":"Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect","volume":"7","author":"Fonollosa","year":"2017","journal-title":"J\u00a0Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.ophtha.2021.05.008_bib20","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma","volume":"7","author":"Welsh","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ophtha.2021.05.008_bib21","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1001\/jamaophthalmol.2014.3024","article-title":"Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib","volume":"132","author":"Guedj","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.05.008_bib22","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/annonc\/mdw100","article-title":"Ocular toxicities of MEK inhibitors and other targeted therapies","volume":"27","author":"Stjepanovic","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ophtha.2021.05.008_bib23","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ctrv.2013.01.003","article-title":"Effect of inhibition of the FGFR\u2013MAPK signaling pathway on the development of ocular toxicities","volume":"39","author":"van der Noll","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ophtha.2021.05.008_bib24","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/IAE.0000000000002451","article-title":"Ocular adverse events associated with MEK inhibitors","volume":"39","author":"M\u00e9ndez-Mart\u00ednez","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2021.05.008_bib25","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.ophtha.2017.11.001","article-title":"Re: Francis et\u00a0al.: Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy (Ophthalmology. 2017;124:1788-1798)","volume":"125","author":"Velez-Montoya","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2021.05.008_bib26","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.ophtha.2017.05.038","article-title":"Clinical and morphologic characteristics of MEK inhibitor\u2013associated retinopathy: differences from central serous chorioretinopathy","volume":"124","author":"Francis","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2021.05.008_bib27","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ophtha.2021.05.008_bib28","doi-asserted-by":"crossref","first-page":"20411","DOI":"10.1073\/pnas.0905833106","article-title":"MEK1 mutations confer resistance to MEK and B-RAF inhibition","volume":"106","author":"Emery","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2021.05.008_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejca.2019.07.016","article-title":"Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management","volume":"119","author":"Gogas","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ophtha.2021.05.008_bib30","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdu169","article-title":"Transient MEK inhibitor-associated retinopathy in metastatic melanoma","volume":"25","author":"Urner-Bloch","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ophtha.2021.05.008_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12348-015-0049-9","article-title":"Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib","volume":"5","author":"Draganova","year":"2015","journal-title":"J\u00a0Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.ophtha.2021.05.008_bib32","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/CMR.0000000000000505","article-title":"Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma","volume":"28","author":"Diamantopoulos","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ophtha.2021.05.008_bib33","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1111\/1346-8138.14200","article-title":"Vogt-Koyanagi-Harada disease-like uveitis induced by vemurafenib for metastatic cutaneous malignant melanoma","volume":"45","author":"Fusumae","year":"2018","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.ophtha.2021.05.008_bib34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case\u2013non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapies"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642021003663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642021003663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:11:16Z","timestamp":1758982276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642021003663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0161642021003663"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2021.05.008","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular Safety Profile of BRAF and MEK Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2021.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}